The Latest Diabetic Retinopathy Industry Statistics Explained
The global Diabetic Retinopathy Market size was valued at USD 7.9 billion in 2019 and is projected to reach USD 13.33 billion by 2027.
The statistic indicates that the market size for Diabetic Retinopathy, a common complication of diabetes that affects the eyes, was valued at USD 7.9 billion in 2019. The projection suggests that the market is expected to increase in value to USD 13.33 billion by the year 2027. This growth in market size reflects the rising prevalence of diabetes worldwide and the subsequent increase in individuals at risk of developing diabetic retinopathy. The expanding market size also highlights the importance of developing and providing effective treatments and technologies to address this growing health concern, driving investment and innovation in the field of diabetic retinopathy management.
North America dominated the global Diabetic Retinopathy Market in 2019.
The statistic “North America dominated the global Diabetic Retinopathy Market in 2019” indicates that North America had the largest market share in terms of revenue and influence in the diabetic retinopathy sector compared to other regions worldwide during that year. This dominance suggests that North America had the most significant presence in terms of companies, research advancements, treatment options, and overall market reach within the diabetic retinopathy market. Factors contributing to this dominance may include high prevalence rates of diabetes, well-developed healthcare infrastructure, strong regulatory frameworks, and robust investment in research and development within North America.
Non-Proliferative Diabetic Retinopathy held the leading share in the Diabetic Retinopathy market in 2019.
In 2019, Non-Proliferative Diabetic Retinopathy (NPDR) accounted for the largest market share within the Diabetic Retinopathy market. This statistic indicates that NPDR, a form of diabetic eye disease characterized by damage to the blood vessels in the retina but without the presence of abnormal blood vessel growth, was the most prevalent and commonly diagnosed type of diabetic retinopathy during that year. This suggests that NPDR had a significant impact on the overall landscape of diabetic retinopathy cases, highlighting the importance of early detection and management of this condition to prevent vision loss and other complications associated with diabetes.
Over 93 million people worldwide were estimated to be affected by diabetic retinopathy in 2019.
In 2019, an estimated 93 million individuals worldwide were affected by diabetic retinopathy, a complication of diabetes that affects the eyes and can lead to vision loss or blindness if left untreated. This statistic highlights the substantial global burden of this sight-threatening condition, emphasizing the importance of early detection and management of diabetes to prevent or slow down the progression of diabetic retinopathy. Efforts to increase awareness, access to screening, and optimal management of diabetes are crucial to reduce the prevalence and impact of diabetic retinopathy on individuals and healthcare systems around the world.
Anti-VEGF drugs segment dominated the diabetic retinopathy market with a significant share.
The statement “Anti-VEGF drugs segment dominated the diabetic retinopathy market with a significant share” suggests that within the market for treating diabetic retinopathy, drugs targeting vascular endothelial growth factor (VEGF) are leading in terms of usage or sales. This dominance indicates that healthcare providers or patients are increasingly utilizing anti-VEGF drugs compared to other medications or treatment approaches for diabetic retinopathy. The significant share implies that a substantial portion of the market is attributed to these drugs, indicating their effectiveness, popularity, or potentially advantages over other treatment options in managing diabetic retinopathy.
It is projected that diabetic retinopathy will affect approximately 191.0 million people by 2030.
The statistic that diabetic retinopathy is projected to affect approximately 191.0 million people by 2030 indicates the expected global burden of this eye condition among individuals with diabetes. Diabetic retinopathy is a common complication of diabetes that can lead to vision impairment and blindness if left untreated. The projection of 191.0 million affected individuals by 2030 highlights the growing challenge of managing diabetic retinopathy on a global scale, emphasizing the importance of raising awareness, implementing effective prevention strategies, and ensuring access to timely screening and treatment services to address this significant public health issue.
The hospital pharmacies segment is projected to have the largest share in the distribution channel of the Diabetic Retinopathy market in 2021.
The statistic stating that the hospital pharmacies segment is projected to have the largest share in the distribution channel of the Diabetic Retinopathy market in 2021 implies that hospital pharmacies are expected to play a significant role in the distribution of medications and products related to Diabetic Retinopathy. This suggests that hospitals serve as key outlets for patients to access essential treatments for the condition. The prominence of hospital pharmacies in this distribution channel likely indicates that they are well-equipped to cater to the specialized needs of patients with Diabetic Retinopathy, offering a wide range of medications, supplies, and services to meet the demands of this particular patient population.
Ophthalmology clinics comprise a significant portion of the diabetic retinopathy market.
This statistic indicates that ophthalmology clinics play a substantial role in the market for diabetic retinopathy, a common complication of diabetes that can lead to vision loss if left untreated. The statement suggests that a significant proportion of patients with diabetic retinopathy receive care or treatment from ophthalmology clinics, highlighting the importance of these specialized healthcare providers in managing this particular condition. This information underscores the crucial role that ophthalmologists and ophthalmology clinics play in diagnosing, monitoring, and treating diabetic retinopathy, potentially influencing healthcare resource allocation and policy decisions related to diabetic eye care.
India and China together contribute around half of the diabetic population worldwide and hence are considered as potential markets for diabetic retinopathy treatment.
The statistic indicates that India and China collectively account for approximately half of the total diabetic population globally. Given the high prevalence of diabetes in these two countries, they are perceived as significant potential markets for diabetic retinopathy treatment. Diabetic retinopathy is a common complication of diabetes that affects the eyes and can lead to vision loss if left untreated. As such, the large diabetic populations in India and China present an opportunity for healthcare providers and pharmaceutical companies to focus on developing and providing effective treatments for diabetic retinopathy in order to meet the needs of these populations and address the growing burden of this condition in these regions.
The emerging nations are expected to follow robust growth in the diabetic retinopathy market during the forecast period.
This statistic suggests that emerging nations are projected to experience significant growth in the market for diabetic retinopathy, a complication of diabetes that affects the eyes. The term “robust growth” indicates strong and substantial expansion in this market segment over the forecast period. This growth can be driven by various factors such as increasing prevalence of diabetes, improved access to healthcare services, advancements in medical technology, and rising awareness about diabetic eye complications in these nations. The statistic highlights the potential opportunities for businesses and healthcare providers in these emerging markets to meet the growing demand for diabetic retinopathy treatments and services.
Major companies operating in the market include Novartis AG, Aerie Pharmaceuticals, etc.
The statistic “Major companies operating in the market include Novartis AG, Aerie Pharmaceuticals, etc.” indicates that within the specific market being analyzed, these companies are significant players and are likely to have a notable influence on industry dynamics and competition. Novartis AG and Aerie Pharmaceuticals are identified as key companies within the market landscape, suggesting they have a significant market share, brand recognition, and likely contribute significantly to industry developments such as research, product innovation, and overall market trends. The inclusion of other companies with the phrase “etc.” further implies that there are additional major players in the market, underscoring the competitive nature of the industry and the diversity of companies that exert influence in the sector.
Diabetic retinopathy caused blindness in almost 5 million people in 2020, and the number is expected to reach 7 million by 2030.
The statistic indicates that diabetic retinopathy, a condition that can lead to blindness, affected nearly 5 million individuals in 2020, and this number is projected to increase to 7 million by 2030. This significant rise in the number of people affected by diabetic retinopathy highlights the growing burden of this disease on global public health. The statistic underscores the importance of proactive measures to prevent, diagnose, and manage diabetic retinopathy to mitigate its impact on individuals’ visual health and overall well-being. Efforts to raise awareness, improve access to healthcare services, and promote healthy lifestyle behaviors are crucial in addressing the growing prevalence of this sight-threatening complication of diabetes.
In the treatment sector, anti-VEGF therapy dominates the market with significant revenue share.
The statistic “In the treatment sector, anti-VEGF therapy dominates the market with significant revenue share” indicates that within the treatment landscape, anti-VEGF therapy holds a prominent position in terms of generating revenue. This suggests that anti-VEGF therapy is a popular and widely adopted treatment option within the market, potentially due to its efficacy and widespread use for various medical conditions. The significant revenue share implies that a large portion of the overall revenue generated in the treatment sector is attributed to anti-VEGF therapy, highlighting its economic importance and market dominance compared to other treatment options. This statistic underscores the commercial success and prominence of anti-VEGF therapy in the healthcare industry.
The Diabetic Retinopathy market in the Asia Pacific is the fastest-growing market globally.
The statistic that the Diabetic Retinopathy market in the Asia Pacific is the fastest-growing market globally signifies that the rate at which this market is expanding exceeds that of any other region internationally. This trend suggests a significant increase in both the prevalence of diabetic retinopathy cases in the Asia Pacific region and the corresponding demand for related products and services. Factors contributing to this rapid growth may include a higher incidence of diabetes in the region, increasing awareness and diagnosis of diabetic retinopathy, advancements in healthcare infrastructure, and a growing geriatric population. Companies operating in the Diabetic Retinopathy market are likely to seize the growth opportunities in the Asia Pacific region by expanding their presence, developing innovative solutions, and catering to the specific needs of the market.
Intraocular Steroid Injection is anticipated to witness the fastest growth during the forecast period.
The statement “Intraocular Steroid Injection is anticipated to witness the fastest growth during the forecast period” indicates that among all the different treatments and interventions available in the eye care industry, the use of intraocular steroid injections is expected to experience the highest rate of increase in terms of demand, utilization, or market penetration within a specified future timeframe. This suggests that there is a rising interest and need for this particular procedure, possibly due to its effectiveness, safety, or other factors compared to alternative treatment options. The forecast points towards a significant growth trajectory for intraocular steroid injections, reflecting a projected shift in the broader landscape of eye care towards this specific treatment modality.
Diabetic retinopathy is the leading cause of blindness in working-age adults
The statistic that “diabetic retinopathy is the leading cause of blindness in working-age adults” highlights the significant impact of diabetes on vision-related complications. Diabetic retinopathy is a condition that affects the blood vessels in the retina due to prolonged high blood sugar levels in individuals with diabetes. Over time, this damage can lead to vision impairment and even blindness if left untreated. The fact that it is the primary cause of blindness in working-age adults emphasizes the importance of managing diabetes effectively to prevent or delay the development of this potentially devastating complication, underscoring the need for regular eye exams and early intervention to protect vision health in diabetic individuals.
The European market for diabetic retinopathy is equally promising owing to the increasing case of diabetes in the region
The statistic referring to the European market for diabetic retinopathy being equally promising highlights the potential opportunities for growth and development in this particular healthcare sector. The statement underscores the fact that the prevalence of diabetes in Europe is on the rise, leading to an increased number of individuals at risk of developing diabetic retinopathy, a serious complication of diabetes that affects the eyes. As more people are diagnosed with diabetes, the demand for diagnostic tools, treatments, and services related to diabetic retinopathy is likely to grow, creating a promising market for healthcare companies and professionals operating in this field. This trend indicates a significant market potential for innovative solutions and interventions aimed at managing and preventing diabetic retinopathy in the European region.
Proliferative diabetic retinopathy is less prevalent as compared to non-proliferative diabetic retinopathy but has a higher risk of causing vision loss.
The statistic suggests that while proliferative diabetic retinopathy is less common than non-proliferative diabetic retinopathy, it poses a greater risk of vision loss. This may be due to the fact that proliferative diabetic retinopathy, characterized by abnormal blood vessel growth in the retina, can lead to more severe complications such as retinal detachment and macular edema, which are major contributors to vision impairment. Therefore, even though fewer individuals may have proliferative diabetic retinopathy compared to non-proliferative diabetic retinopathy, the potential for vision loss is greater in this condition, underscoring the importance of early detection and treatment to prevent serious visual complications.
Early detection through regular eye examinations can reduce the risk of blindness due to diabetic retinopathy by 95%.
This statistic suggests that individuals with diabetes who undergo regular eye examinations have a significantly lower risk of experiencing blindness as a result of diabetic retinopathy compared to those who do not. More specifically, the risk of blindness due to diabetic retinopathy can be reduced by a striking 95% through early detection facilitated by routine eye examinations. This highlights the critical importance of proactive eye care for diabetic patients in mitigating the potentially severe consequences of diabetic retinopathy, a common complication of diabetes that can lead to vision loss and blindness if left untreated. Regular eye screenings can thus play a pivotal role in identifying any abnormalities in the retina at an early stage, enabling timely intervention and management to prevent or delay vision impairment.
References
0. – https://www.www.marketdataforecast.com
1. – https://www.www.who.int
2. – https://www.www.cdc.gov
3. – https://www.www.grandviewresearch.com
4. – https://www.www.globenewswire.com
5. – https://www.www.fortunebusinessinsights.com
